France-based company specialized in developing therapeutic peptides for rare endocrine and related diseases
Amolyt Pharma has raised €129M across 1 funding round from 16 investors, most recently a Series C round in Jan 2023. Based in Lyon, France; active in Healthtech. Data as of 6 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-01-09 | Series C | €129M |
| Andera Partners,ATEM,Credit Agricole Creation,CTI Life Sciences,EQT Life Sciences,Innobio 2+10 more |
| View deal → |
